What is the recommended syringe size, 1ml or 3ml, for injecting triamcinolone (Kenalog) into keloid scars?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

For intramuscular or intra-articular use only KENALOG-40 40 mg per 10 mL Injectable Suspension 1 mL Single-Dose Vial 5 mL Multiple-Dose Vial 10 mL Multiple-Dose Vial

The recommended dosage for keloid scars is not explicitly stated in the drug label. However, considering the available syringe sizes (1 mL, 5 mL, 10 mL), a 1 mL syringe can be used to inject triamcinolone for keloid scars, as it is a single-dose vial option.

  • Key consideration: The label does not provide specific guidance on the treatment of keloid scars, so caution should be exercised when making clinical decisions. 1

From the Research

For injecting keloid scars with triamcinolone, a 1ml syringe is generally preferred over a 3ml syringe. The 1ml syringe allows for more precise dosing and better control during the injection procedure, which is particularly important when treating keloid scars that may require small amounts of medication in specific areas. Typically, triamcinolone acetonide is used at concentrations ranging from 10-40 mg/ml depending on the size, location, and thickness of the keloid, as supported by studies such as 2. The injection should be performed using a 27-30 gauge needle to minimize discomfort and tissue trauma. When administering the injection, insert the needle into the body of the keloid and inject the medication slowly until slight blanching occurs. Multiple small injections throughout the keloid are often more effective than a single large injection. Treatments are usually repeated every 3-4 weeks until the desired result is achieved.

Some key considerations include:

  • Starting with lower concentrations (10-20 mg/ml) is advisable for facial keloids or in patients with darker skin tones to minimize side effects such as skin atrophy, hypopigmentation, and telangiectasia, as noted in 3.
  • The use of triamcinolone acetonide has been shown to be effective in reducing the size of keloid scars compared to untreated controls, as demonstrated in 4.
  • Combination therapies, such as the use of triamcinolone acetonide with 5-fluorouracil, may offer benefits in terms of reduced side effects and improved efficacy, as suggested by 3.

Overall, the choice of syringe size and injection technique should be guided by the specific needs of the patient and the characteristics of the keloid scar, with the goal of minimizing morbidity, mortality, and improving quality of life.

Related Questions

What is the recommended time frame after completing triamcinolone (Kenalog) injections for keloid treatment to initiate laser therapy?
What is the recommended time interval after completing triamcinolone (corticosteroid) injections for keloid treatment before initiating superficial radiotherapy?
What is the most effective corticosteroid (steroid) for intralesional injection in the treatment of keloid scars?
What are the guidelines for steroid (corticosteroid) injections, including indications and contraindications, for the treatment of acne and keloids?
What is the maximum duration for using corticosteroids (steroids) to treat keloids before skin atrophy becomes a concern?
Is stem cell therapy effective for wrist osteoarthritis (Degenerative Joint Disease)?
What are the treatment options for a patient presenting with numbness in the legs, loss of balance, interdigital blisters, peripheral neuropathy in the feet, nocturnal foot pain, and tingling sensations in the feet and knees, with a diagnosis of multilevel chronic degenerative spondylosis, stable Grade 2 anterolisthesis of L4 (Lumbar vertebra 4) on L5 (Lumbar vertebra 5), and moderate spinal canal stenosis?
Should laxative weaning be initiated in a patient with constipation, currently on Senna (Sennoside) 17.2 mg twice daily (BID), Polyethylene Glycol (PEG) 17 g BID, Bisacodyl 10 mg orally daily, Bisacodyl 10 mg suppository, and Lactulose 20 mg daily, after starting Linaclotide (Linaclotide)?
What is the management for a 33-year-old female patient presenting to the Emergency Room (ER) with acute diffuse abdominal pain, nausea, and a history (hx) of diverticulitis, diagnosed with cecal diverticulitis on computed tomography (CT) scan, and indicated for ileocecal resection?
What is the treatment for headache (HA) lasting over 24 hours with associated sinus pressure?
What are the effects of Copastin (Baclofen) in an 11-year-old?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.